These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 23902247)

  • 1. Skin toxicity of targeted cancer agents: mechanisms and intervention.
    Belum VR; Fontanilla Patel H; Lacouture ME; Rodeck U
    Future Oncol; 2013 Aug; 9(8):1161-70. PubMed ID: 23902247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toxicity of targeted therapy: Implications for response and impact of genetic polymorphisms.
    Liu S; Kurzrock R
    Cancer Treat Rev; 2014 Aug; 40(7):883-91. PubMed ID: 24867380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
    Faivre S; Djelloul S; Raymond E
    Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular toxicity associated with small molecule tyrosine kinase inhibitors currently in clinical use.
    Dasanu CA; Padmanabhan P; Clark BA; Do C
    Expert Opin Drug Saf; 2012 May; 11(3):445-57. PubMed ID: 22469002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cutaneous side effects of inhibitors of the RAS/RAF/MEK/ERK signalling pathway and their management.
    Manousaridis I; Mavridou S; Goerdt S; Leverkus M; Utikal J
    J Eur Acad Dermatol Venereol; 2013 Jan; 27(1):11-8. PubMed ID: 22540151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of inhibition of the FGFR-MAPK signaling pathway on the development of ocular toxicities.
    van der Noll R; Leijen S; Neuteboom GH; Beijnen JH; Schellens JH
    Cancer Treat Rev; 2013 Oct; 39(6):664-72. PubMed ID: 23434072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protein kinases as targets for cancer treatment.
    Giamas G; Stebbing J; Vorgias CE; Knippschild U
    Pharmacogenomics; 2007 Aug; 8(8):1005-16. PubMed ID: 17716234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic protein kinase inhibitors.
    Grant SK
    Cell Mol Life Sci; 2009 Apr; 66(7):1163-77. PubMed ID: 19011754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-vascular endothelial growth factor therapy in the era of personalized medicine.
    Féliz LR; Tsimberidou AM
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):1-12. PubMed ID: 23463481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Management of adverse effects of targeted therapy toxicities in oncology].
    Coquan E; Henri P; de Raucourt S; Lireux B; Lamy E; Delcambre C; Sevin E; Dutriaux C; Bouhier-Leporrier K; Gervais R; Joly F
    Rev Prat; 2012 Jan; 62(1):17-25. PubMed ID: 22335060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential splicing generates new transmembrane receptor and extracellular matrix-related targets for antibody-based therapy of cancer.
    Weidle UH; Maisel D; Klostermann S; Weiss EH; Schmitt M
    Cancer Genomics Proteomics; 2011; 8(5):211-26. PubMed ID: 21980036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
    Gollob JA; Wilhelm S; Carter C; Kelley SL
    Semin Oncol; 2006 Aug; 33(4):392-406. PubMed ID: 16890795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Management of cutaneous adverse events induced by molecularly-targeted drugs].
    Nakahara T
    Fukuoka Igaku Zasshi; 2014 Sep; 105(9):175-81. PubMed ID: 25639024
    [No Abstract]   [Full Text] [Related]  

  • 14. RAF inhibition and induction of cutaneous squamous cell carcinoma.
    Robert C; Arnault JP; Mateus C
    Curr Opin Oncol; 2011 Mar; 23(2):177-82. PubMed ID: 21192261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cutaneous reactions related to systemic immunomodulators and targeted therapeutics.
    Hammond-Thelin LA
    Dermatol Clin; 2008 Jan; 26(1):121-59, ix. PubMed ID: 18023775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Skin cancer chemopreventive effects of a flavonoid antioxidant silymarin are mediated via impairment of receptor tyrosine kinase signaling and perturbation in cell cycle progression.
    Ahmad N; Gali H; Javed S; Agarwal R
    Biochem Biophys Res Commun; 1998 Jun; 247(2):294-301. PubMed ID: 9642119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cutaneous Adverse Events of Targeted Therapies for Hematolymphoid Malignancies.
    Ransohoff JD; Kwong BY
    Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):834-851. PubMed ID: 28918995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dermatological side effects of current and upcoming targeted therapies in oncology.
    Bonny M; Buyse V; Brochez L
    Acta Clin Belg; 2011; 66(2):97-103. PubMed ID: 21630605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse events of targeted therapies.
    Klastersky JA
    Curr Opin Oncol; 2014 Jul; 26(4):395-402. PubMed ID: 24825019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in the management of cutaneous toxicities of targeted therapies.
    Robert C; Sibaud V; Mateus C; Cherpelis BS
    Semin Oncol; 2012 Apr; 39(2):227-40. PubMed ID: 22484194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.